ADAPTIVE BIOTECHNOLOGIES CORPORATION: operating cash flow
Operating cash flow for ADAPTIVE BIOTECHNOLOGIES CORPORATION. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ADAPTIVE BIOTECHNOLOGIES CORPORATION financial histories
What this measure means
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
Exact concept: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -45,986,000 | USD | 2026-02-26 | 10-K · 0001193125-26-076902 |
| 2024-01-01 | 2024-12-31 | -95,212,000 | USD | 2026-02-26 | 10-K · 0001193125-26-076902 |
| 2023-01-01 | 2023-12-31 | -156,324,000 | USD | 2026-02-26 | 10-K · 0001193125-26-076902 |
| 2022-01-01 | 2022-12-31 | -183,945,000 | USD | 2025-03-03 | 10-K · 0000950170-25-030913 |
| 2021-01-01 | 2021-12-31 | -192,727,000 | USD | 2024-02-29 | 10-K · 0000950170-24-023095 |
| 2020-01-01 | 2020-12-31 | -149,683,000 | USD | 2023-02-14 | 10-K · 0000950170-23-002792 |
| 2019-01-01 | 2019-12-31 | 205,404,000 | USD | 2022-02-15 | 10-K · 0001564590-22-005228 |
| 2018-01-01 | 2018-12-31 | -32,259,000 | USD | 2021-02-24 | 10-K · 0001564590-21-008124 |
| 2017-01-01 | 2017-12-31 | -34,858,000 | USD | 2020-02-26 | 10-K · 0001564590-20-006830 |
Related financial histories
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: total assets
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: total liabilities
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: stockholders equity
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: cash and cash equivalents
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: net income or loss
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: capital expenditure payments
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: contract revenue excluding tax
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: financing cash flow
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: investing cash flow
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: retained earnings or deficit
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: basic weighted-average shares
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: diluted weighted-average shares
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: basic earnings per share
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: diluted earnings per share
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: net property, plant and equipment
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: share-based compensation expense
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: operating income or loss
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: current assets
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: interest expense
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: current liabilities
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: current accounts payable
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: goodwill carrying amount
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: net finite-lived intangible assets
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: net current accounts receivable
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: net inventory
- ADAPTIVE BIOTECHNOLOGIES CORPORATION: research and development expense
Inspect the source
- Entity
- ADAPTIVE BIOTECHNOLOGIES CORPORATION / CIK 0001478320
- Captured
- 2026-09-20T09:08:39.352Z
- SEC response SHA-256
2deab3b0302b42f5bca7f049684da17a3e834dfbc3dbe128e51ed398b3d69a92
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001478320.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))